about
Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART durationDevelopment and evaluation of a baseline-event-anticipation score for hepatitis deltaEfficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation.Plasma interleukin-18 reflects severity of ulcerative colitis.Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland.Effect of psoriasis activity on serum adiponectin and leptin levels.Specific ssDNA concentration in liver tissue as an index of apoptosis in hepatitis C virus-infected patients.Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern PolandAcute hepatitis E complicated by acute pancreatitis: a case report and literature review.Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.A pill for HCV - myth or foreseeable future?Emerging treatments for hepatitis C.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease.Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients.Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease.Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease.Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults.Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients.Pigment epithelium-derived factor in ulcerative colitis: possible relationship with disease activity.Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales.Metabolic syndrome and hepatitis C infection--brothers in arms.Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.[Treatment recommendations of chronic hepatitis B. Did the world escape us?].Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients.Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?Serum adiponectin and leptin levels in psoriatic patients according to topical treatment.Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales.siRNA drug development against hepatitis B virus infectionPredictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patientsThe interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver diseaseReal World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free TherapyChronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients
P50
Q28262985-7BD6467C-50D3-4120-9BEB-1A2D46F6ADCEQ33414249-11A9EA11-E9BC-4A0E-B5EE-49BD349FF5EEQ34382319-4EC1C17D-10E7-4EE1-BC09-A95AC54E2B83Q34605860-D2DFEB0D-51B4-499D-8EF6-DF4E60D5BA36Q35010645-8F6B5C92-7488-4738-884C-ED561809C72AQ35620533-7799AF72-3D5E-45A2-8E1E-3215A92EC469Q35621316-1F1CE192-5681-4862-A810-9A0CF68D5609Q35964789-C367D2A2-7E11-419F-B949-778EB9B46716Q36102607-E18AB8F5-EABD-45B6-AB1A-CDB5F43C18A0Q36180595-9BAC203F-8584-41B2-B263-1B32F8A5D332Q38133640-9945B283-73B2-47C2-94F5-5FAD1EBA692EQ38150403-9E8CEF1A-4DE5-4C10-9B48-9CE4434EF553Q38540088-130B649B-98D4-40D5-83DC-927854165BE0Q39406860-596F6670-A741-4E48-A481-939BFFAA9B2AQ39723501-E2FEE9E5-6C55-4523-A18B-9927E7A6FC6AQ40084913-0C8E42ED-FCB0-4D92-81C8-804395484B68Q41325916-16FED464-C550-46BB-B525-B0080D8F2DF0Q41472788-DA28262E-EADD-4EC5-ACFE-4055B7E5F230Q41664208-6B9845B3-5334-45F0-B407-7B1CF6DB1CFAQ41996933-4A468137-DCAB-4E67-9673-74E61CF5E503Q42249715-49CBE740-2E68-4ECC-96DA-AF5AEEAA963CQ42251249-B9F1D969-60CC-412A-8821-28171E2708E9Q43031484-D177135F-D491-43A3-8D37-F148D99B310EQ43550065-0A18FF13-034B-4492-B8A8-B11258A825EFQ43985033-0485818F-642C-4195-A2D0-875300274E16Q44468791-77D3B62C-FDA3-4801-A78A-25C4A86CCFD7Q44642331-631D4998-0FBD-45D5-9C57-6F031D3A8881Q45158588-0BB421ED-BF10-4E62-9EC1-1107A513C674Q45364954-D8BCAF73-F542-4E2F-A8EF-BCE466729181Q46554449-F1A6C861-892F-4016-B642-9C382B5CA4EAQ47189085-8B8471C0-DE8F-4D31-8494-333359A7058DQ47958615-C815225D-9AEB-483A-86E3-A6A066736897Q50004244-4D6BC482-4858-49AC-9264-9955D2C73FF6Q54273992-46178F29-A18E-45B6-8804-376573EDEC58Q54637916-7CA19A1F-0FFA-451E-888A-201CA07072B7Q59349044-53F39C71-1BC4-480C-B3E1-2AC74322E34EQ60920545-914C2D83-2998-442B-985E-0616C87E40F3Q63805098-E1B0EBA2-D407-4419-ACCD-861D23DD8749Q64070542-BBB10146-FEA9-4D72-917D-88E1F9E7679EQ64276761-F66F4859-03B2-4DD2-B1E3-59B72BAB3A97
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
Jerzy Jaroszewicz
@en
Jerzy Jaroszewicz
@nl
Jerzy Jaroszewicz
@pl
type
label
Jerzy Jaroszewicz
@en
Jerzy Jaroszewicz
@nl
Jerzy Jaroszewicz
@pl
prefLabel
Jerzy Jaroszewicz
@en
Jerzy Jaroszewicz
@nl
Jerzy Jaroszewicz
@pl
P106
P31
P3124
P496
0000-0003-0139-4753